Tofogliflozin | B2083

Tofogliflozin is a potent, and highly selective SGLT2 inhibitor that has been shown to improve glycemic control in diabetic mice and rats. Potential drug for treatment of type 2 diabetes.

Tofogliflozin is a potent, and highly selective SGLT2 inhibitor that has been shown to improve glycemic control in diabetic mice and rats. Potential drug for treatment of type 2 diabetes.

B2083 | Tofogliflozin DataSheet

Alternate Name/Synonyms: (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol; CSG452

Appearance: White solid

Formulation: N/A

CAS Number: 903565-83-3

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₂H₂₆O₆

Molecular Weight: 386.44

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor

MDL Number: MFCD27665464

PubChem CID: 46908929

SMILES: CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2

InChi: InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1

InChi Key: VWVKUNOPTJGDOB-BDHVOXNPSA-N